Experimental TIL therapy for advanced gynecological tumors shows early promise but study halted
NCT ID NCT06191900
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new treatment called GT201 for people with advanced gynecological tumors, like advanced cervical cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight the cancer. The study was terminated early after enrolling only 4 participants, and its main goal was to check the safety and side effects of the therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- What does a healthy mouth mean for people with disabilities?
- Hidden toll of routine ICU procedure revealed: suctioning may spike pain and stress
- New drug duo takes on recurrent brain cancer
- Spinach showdown: does how It's grown affect your blood pressure?
- Video instruction may cut medication errors in kidney transplant patients
- Bone marrow secrets could predict chemo success in leukemia